2024 International Congress » Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)

Meeting: 2024 International Congress

A Phase 1b Randomized, Placebo-Controlled, Delayed-Start Trial of UB-312 in Synucleinopathies.

P. Millar Vernetti, D. Mirski, JC. Dodart, A. Wood, HJ. Yu, J. Boyd, P. Kundu, R. Setton, D. Silbersweig, E. Stern, C. Lucero, S. Gerrol, H. Kaufmann, J. Martinez (New York, USA)

A Randomized, Double-blind, Phase 2a Clinical Trial to Study the Efficacy and Safety of Lamotrigine for Treatment of Patients with Dementia with Lewy Bodies

T. Xi, S. Kang, F. Kim, A. Schindler, D. Greeley, J. Choung, M. Yun, B. Ye (San Diego, USA)

Benefits of Exercise on Mobility, Balance, and Cognition in Community-Dwelling Older Adults: An On-Land vs. In-Water Comparison Study

G. Christofoletti, R. de Oliveira, T. Lino, T. Pontin, C. Lorentz, L. Souza, L. Dias (Campo Grande, Brazil)

Clinical and Neurophysiological Response of Different Protocols of Non-Invasive Spinal Neuromodulation in Anti-Gad Positive Stiff Person Syndrome: A Case Report

V. Maciel, G. Silva, R. Carra, J. Baima, J. Oliveira, M. Silva, P. Lacerda, K. Massruha, C. Heise, C. Tanaka, R. Cury (São Paulo, Brazil)

Ecopipam does not adversely affect Metabolic Parameters in Pediatric Subjects with Tourette Syndrome: Results from a Phase 2b with 12-month Open Label Extension Study

D. Gilbert, S. Atkinson, G. Karkanias, F. Munschauer, S. Wanaski, T. Cunniff (Cincinnati, USA)

Essential3: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide

R. Able, M. Giroux, J. Zhao, H. Jacotin, M. Sniecinski, A. Samaroo, A. La Croix, A. Wyant, C. Santos, M. Souza (Boston, USA)

Improvement in Upright Stability subscale of mFARS with Vatiquinone Treatment in MOVE-FA: a Phase 3, Double-blind, Placebo-controlled Trial

D. Lynch, A. Duquette, M. França Jr, S. Perlman, A. Durr, E. Bertini, A. Darling, K. Mathews, L. Schöls, A. Fournier, M. Delatycki, S. Subramony, R. Roxburgh, O. Zhang, C. Rummey, A. Salvucci, B. Yao, J. Cherry, L. Golden, T. Zesiewicz (Philadelphia, USA)

Incorporating the Voice of the Patient and Caregiver into a Multiple System Atrophy (MSA) clinical trial

J. Marer, G. Krog, D. Houghton, J. Nettleship, M. Chen, L. Marinelli (Netanya, Israel)

Long-term Safety of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension

R. Freeman, I. Biaggioni, R. Vickery, L. Norcliffe-Kaufmann, T. Guerin, M. Bryarly, V. Iodice, M. Rudzniska-Bar, M. Boczarska-Jedynak, C. Oehlwein, C. Shibao, H. Kaufmann (Boston, USA)

Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes (NORAPS). A Phase II clinical trial – ISRCTN99462035.

R. Durcan, J. Rowe (Cambridge, United Kingdom)

Once-Daily Suvecaltamide Pharmacokinetics, Safety, & Tolerability–Phase 1, Randomized, Double-Blind, Multiple Ascending Dose Study

S. Markova, M. Baladi, M. Lee, C. Chen (Palo Alto, USA)

ORION: A Global Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009)

A-M. Wills, G. Höglinger, L. Mehta, M. Leinders, Y. Wu, J. Timmons, A. Hayden, I. Aiba, A. Antonini, A. Boxer, Y. Compta, J-C. Corvol, A. Lang, H. Morris, P. Svenningsson, H. HENRIK.ZETTERBERG@CLINCHEM.GU.SE, L. Golbe (Boston, USA)

Patient Characteristics and Real-World Use of Botulinum Toxins for Treatment of Chronic Sialorrhea

M. Hast, A. Kong, J. Abdelhadi, A. Szendrey, R. Shah, J. Holmes (Raleigh, USA)

Refining Aesthetic Eyebrows: Botulinum Toxin Injection for Hemifacial Spasm.

S. Maytharakcheep, R. Bhidayasiri, O. Phokaewvarangkul (Bangkok, Thailand)

Safety and Efficacy of Vatiquinone Treatment in Friedreich Ataxia Patients from MOVE-FA: a Phase 3, Double-blind, Placebo-controlled Trial

Safety and Tolerability of Ecopipam in Tourette Syndrome (TS) with Psychiatric Comorbidities.

D. Gilbert, S. Atkinson, G. Karkanias, R. Munschauer, S. Wanaski, T. Cunniff (Cincinnati, USA)

SAGE-324/BIIB124, an investigational GABAA receptor PAM, for treatment of essential tremor

P. Lewitt, H. Jinnah, R. Pahwa, A. Ellenbogen, R. Kumar, TM. Lieu, B. Hersh, R. Chuang, C. Vaudreuil, Z. Berger, D. Arkilo, SH. Kuo (Bloomfield, USA)

SNCA Antisense Oligonucleotide for Multiple System Atrophy: HORIZON Trial Update

K. Meilleur, K. Seppi, F. Krismer, R. Simoes, T. Lampreia, J. Corvol, S. Sambin, G. Hoglinger, C. Schindler, A. Schnitzler, C. Hartmann, K. Eggert, H. Pape, A. Ludolph, J. Kassubek, O. Rascol, M. Rumbel, D. Schulz, S. Darrow, Y. Deng, P. Gupta, S. Stanton, J. Esteban, H. Zhao, M. Yarborough, R. Fong (Carlsbad, USA)

Spectrum of Movement disorders, Imaging findings in SSPE and response to therapy – A prospective cohort study

A. Elavarasi, D. Dash, M. Tripathi, R. Singh, D. Vibha, A. Garg (New Delhi, India)

Sympathetic Nervous System Overactivity in the Pre-Motor Stage of Parkinson’s Disease: Therapeutic Implications

M. Tagliati, M. Gregorio, H. Maghzi, G. Obialisi, E. Hogg, C. Malatt, E. Tan, M. Kelly, H. Pomeroy, R. Artal, M. Shehata, B. Renner, Z. Fan, P. Sati, G. Pagano (Los Angeles, USA)

« View all sessions from the 2024 International Congress.